About
Enlivex Therapeutics is a clinical-stage company focused on macrophage reprogramming. The company intends to develop and commercialize a drug pipeline for macrophage reprogramming in solid cancers, sepsis, COVID-19, and other indications. The company's most advanced product candidate, Allocetra, was developed for the reprogramming of diseased macrophages in patients with sepsis or COVID-19, and has demonstrated positive safety, tolerability, and efficacy in several clinical trials. In March 2019, the company announced the completion of its merger with Tel Aviv-headquartered Bioblast Pharma. Following the reverse merger, Enlivex became a subsidiary of Bioblast, which was renamed Enlivex Therapeutics.
Funding history · 4 rounds · $286.9M total
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- What was a significant corporate development for Enlivex Therapeutics in March 2019?
- In March 2019, Enlivex Therapeutics completed a merger with Tel Aviv-headquartered Bioblast Pharma. Following this reverse merger, Enlivex became a subsidiary of Bioblast, which was then renamed Enlivex Therapeutics.
- When did Enlivex Therapeutics become a public company on NASDAQ?
- Enlivex Therapeutics became public on NASDAQ in March 2019.
- What was the total amount raised by Enlivex Therapeutics in funding rounds?
- According to startupim data, Enlivex Therapeutics has raised a total of $286,900,000 USD in funding.
- What was the most recent funding round for Enlivex Therapeutics, and when did it occur?
- The most recent funding round for Enlivex Therapeutics was a PIPE round in November 2025, which raised $212,000,000 USD.
- Which investors participated in Enlivex Therapeutics' Series B round in September 2017?
- The Series B round in September 2017 included investors Hadasit Bio-Holdings and Korea Investment Partners.
- What is Enlivex Therapeutics' most advanced product candidate and its primary indications?
- Enlivex Therapeutics' most advanced product candidate is Allocetra, developed for reprogramming diseased macrophages in patients with sepsis or COVID-19.
- What was the amount of the grant Enlivex Therapeutics received from the IIA in May 2021?
- In May 2021, Enlivex Therapeutics received a grant of $1,100,000 USD from the IIA.
- When did Enlivex Therapeutics announce positive interim data for Allocetra in patients with moderate to severe knee osteoarthritis?
- In March 2025, Enlivex announced positive interim data for Allocetra, showing a statistically significant 47.0% durable and persistent pain reduction at six months in patients with moderate to severe knee osteoarthritis.
- What regulatory authorization did Enlivex Therapeutics receive in December 2024?
- In December 2024, Enlivex Therapeutics received Israeli regulatory authorization to commence a Phase I trial evaluating Allocetra in patients with TMJ osteoarthritis.
- What was a key development regarding Allocetra's patent coverage in February 2024?
- In February 2024, Enlivex announced the issuance of a new U.S. patent covering Allocetra cells and their manufacturing method.